Literature DB >> 9219514

The retinoblastoma protein: a master regulator of cell cycle, differentiation and apoptosis.

S Herwig1, M Strauss.   

Abstract

The retinoblastoma susceptibility gene is a tumour suppressor and its product retinoblastoma protein (pRb) has been known for 10 years as a repressor of progression towards S phase. Its major activity was supposed to be sequestration or inactivation of the transcription factor E2F which is required for activation of S phase genes. However, within recent years growing evidence has been accumulating for a more general function of pRb at both the transcriptional level and the cellular level. pRb not only regulates the activity of certain protein-encoding genes but also the activity of RNA polymerase pol I and pol III transcription. This protein appears to be the major player in a regulatory circuit in the late G1 phase, the so-called restriction point. Moreover, it is involved in regulating an elusive switch point between cell cycle, differentiation and apoptosis. Here, it seems to cooperate with another major tumour suppressor, p53. Thus, pRb sits at the interface of the most important cell-regulatory processes and therefore deserves close attention by specialists from different fields of research. This review provides an introduction to the complex functions of pRb.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9219514     DOI: 10.1111/j.1432-1033.1997.t01-2-00581.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  60 in total

1.  Cumulative effect of phosphorylation of pRB on regulation of E2F activity.

Authors:  V D Brown; R A Phillips; B L Gallie
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

2.  A geminivirus replication protein interacts with the retinoblastoma protein through a novel domain to determine symptoms and tissue specificity of infection in plants.

Authors:  L J Kong; B M Orozco; J L Roe; S Nagar; S Ou; H S Feiler; T Durfee; A B Miller; W Gruissem; D Robertson; L Hanley-Bowdoin
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

3.  The MRE11-NBS1-RAD50 pathway is perturbed in SV40 large T antigen-immortalized AT-1, AT-2 and HL-1 cardiomyocytes.

Authors:  N A Lanson; D B Egeland; B A Royals; W C Claycomb
Journal:  Nucleic Acids Res       Date:  2000-08-01       Impact factor: 16.971

4.  Overlapping functions of the pRb family in the regulation of rRNA synthesis.

Authors:  S Ciarmatori; P H Scott; J E Sutcliffe; A McLees; H M Alzuherri; J H Dannenberg; H te Riele; I Grummt; R Voit; R J White
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

5.  RNA polymerase III transcription factor IIIB is a target for repression by pocket proteins p107 and p130.

Authors:  J E Sutcliffe; C A Cairns; A McLees; S J Allison; K Tosh; R J White
Journal:  Mol Cell Biol       Date:  1999-06       Impact factor: 4.272

6.  The interferon-inducible nucleolar p204 protein binds the ribosomal RNA-specific UBF1 transcription factor and inhibits ribosomal RNA transcription.

Authors:  C J Liu; H Wang; P Lengyel
Journal:  EMBO J       Date:  1999-05-17       Impact factor: 11.598

Review 7.  RNA polymerase III transcription: its control by tumor suppressors and its deregulation by transforming agents.

Authors:  T R Brown; P H Scott; T Stein; A G Winter; R J White
Journal:  Gene Expr       Date:  2000

8.  Two E2F elements regulate the proliferating cell nuclear antigen promoter differently during leaf development.

Authors:  Erin M Egelkrout; Luisa Mariconti; Sharon B Settlage; Rino Cella; Dominique Robertson; Linda Hanley-Bowdoin
Journal:  Plant Cell       Date:  2002-12       Impact factor: 11.277

9.  Retinoblastoma protein disrupts interactions required for RNA polymerase III transcription.

Authors:  J E Sutcliffe; T R Brown; S J Allison; P H Scott; R J White
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

Review 10.  Cell cycle genes in a mouse mammary hyperplasia model.

Authors:  Thenaa K Said; Daniel Medina
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.